SSSriram Sundaravel

Sriram Sundaravel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sriram Sundaravel has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

    by Goichi Tatsumi, Rajni Kumari, Yutaro Suzuki, Shuting Li, Russell Scharf, Samuel J. Taylor, Sriram Sundaravel, Amit Verma, Justin C. Wheat, Ulrich Steidl

    Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.

  • Open Access

    Supplementary Tables S1-S6 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

    by Goichi Tatsumi, Rajni Kumari, Yutaro Suzuki, Shuting Li, Russell Scharf, Samuel J. Taylor, Sriram Sundaravel, Amit Verma, Justin C. Wheat, Ulrich Steidl

    Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.

  • Open Access

    Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

    by Goichi Tatsumi, Rajni Kumari, Yutaro Suzuki, Shuting Li, Russell Scharf, Samuel J. Taylor, Sriram Sundaravel, Amit Verma, Justin C. Wheat, Ulrich Steidl

    Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

  • Open Access

    Supplementary Figures S1-S9 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

    by Goichi Tatsumi, Rajni Kumari, Yutaro Suzuki, Shuting Li, Russell Scharf, Samuel J. Taylor, Sriram Sundaravel, Amit Verma, Justin C. Wheat, Ulrich Steidl

    Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.

  • Open Access

    Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia

    by Goichi Tatsumi, Rajni Kumari, Yutaro Suzuki, Shuting Li, Russell Scharf, Samuel J. Taylor, Sriram Sundaravel, Amit Verma, Justin C. Wheat, Ulrich Steidl

    Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.

  • Open Access

    A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm

    by Richard T. Piszczatowski, Emily Schwenger, Sriram Sundaravel, Catarina M. Stein, Yang Liu, Pamela Stanley, Amit Verma, Deyou Zheng, Ronald D. Seidel, Steven C. Almo, et al.

    Cell surfaces display a wide array of molecules that confer identity. While flow cytometry and cluster of differentiation (CD) markers have revolutionized cell characterization and purification, functionally heterogeneous cellular subtypes remain unresolvable by the CD marker system alone. Using hematopoietic lineages as a paradigm, we leverage the extraordinary molecular diversity of heparan sulfate (HS) glycans to establish cellular “glycotypes” by utilizing a panel of anti-HS single-chain variable fragment antibodies (scFvs). Prospective sorting with anti-HS scFvs identifies functionally distinct glycotypes within heterogeneous pools of mouse and human hematopoietic progenitor cells and enables further stratification of immunophenotypically pure megakaryocyte–erythrocyte progenitors. This stratification correlates with expression of a heptad of HS-related genes that is reflective of the HS epitope recognized by specific anti-HS scFvs. While we show that HS glycotyping provides an orthogonal set of tools for resolution of hematopoietic lineages, we anticipate broad utility of this approach in defining and isolating novel, viable cell types across diverse tissues and species.